Listen Up

Monday, July 22, 2024

A Parent’s Guide to Internet Safety for Kids

 

Many studies reveal how the internet affects the mental health of children.

The impact of the internet on the mental health of children is a complex and nuanced issue. Here are some key ways the internet can affect children's mental health:


There are some positive as well as negative impacts.

Positive impacts:

Access to information and educational resources can support learning and development. Opportunities for social connection and community building can reduce isolation. Exposure to diverse perspectives and ideas that can broaden horizons. Outlets for self-expression and creativity.

Negative impacts:

Excessive screen time and internet use can disrupt sleep, physical activity, and face-to-face social interaction. Exposure to cyberbullying, trolling, and other harmful online behaviors can contribute to anxiety, depression, and low self-esteem. Access to inappropriate or disturbing content that may be psychologically distressing. Social comparison and feelings of inadequacy from seeing idealized content on social media.  Addiction-forming behaviors from excessive internet and social media use. The degree of impact often depends on factors like the child's age, maturity, mental health, and parental mediation and guidance. While the Internet provides many benefits, it's important for parents and caregivers to monitor and moderate children's online activities to mitigate potential mental health risks. A balanced approach that promotes healthy online and offline activities is generally recommended.

Teaching kids about Internet safety

In today's world, the pace of change is rapid, and parents cannot keep up.  On the other hand, our children thrive on new technology and social media. 

If you want to learn more about technology, the internet, and computers I recommend this website

Stay sane and keep those little ones safe.  Courtesy of  Nicole You may reach her at  nicole@onlinesafetymasters.com

ref:

Title: "The Impact of Digital Technology on Children's Well-Being"Authors: Przybylski, A. K., & Weinstein, N.Journal: Pediatrics, 140(Supplement 2), S86-S91. Publication Date: 2017

Title: "The Impact of Social Media Use on Children's and Adolescents' Mental Health" Authors: Hollis, C., Livingstone, S., & Sonuga-Barke, E.Journal: The Lancet Child & Adolescent Health, 4(5), 337-343. Publication Date: 2020 Key Findings:

 Authors: Hale, L., & Guan, S.Journal: Child Development, 86(1), 45-63.Publication Date: 2015 Key Findings:

 Title: "The Impact of Excessive Internet and Smartphone Use on Mental Health: A Systematic Review" Authors: Király, O., Potenza, M. N., Stein, D. J., King, D. L., Hodgins, D. C., Saunders, J. B., ... & Demetrovics, Z.Journal: Journal of Behavioral Addictions, 9(4), 1031-1064. 2020Publication Date:  

If you want to read more about this issue. 

https://zentrointernet.com/a-parents-guide-to-internet-safety-for-kids/

Thursday, July 18, 2024

Is Everything Health Care? The Overblown Social Determinants of Health | Manhattan Institute

In November 2023, the Biden White House released the 53-page U.S. Playbook to Address Social Determinants of Health and declared: “Improving health and well-being across America requires addressing the social circumstances and related environmental hazards and exposures that improve health outcomes.” It accepted the Department of Health and Human Services’ definition of SDOH as “the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks.”[1]


The same month as the
 Playbook’s release, federal regulations revising Medicare payments to physicians declared that “around 50 percent of an individual’s health is directly related to SDOH.”[2] Others have suggested that 40% to 90% of health outcomes are attributable to social, behavioral, or economic factors.[3]

These claims are based on some stark facts. Low-income Americans have higher rates of disability, anxiety, heart disease, stroke, diabetes, and other chronic conditions, and they are more subject to obesity, substance abuse, physical strain, and environmental pollutants.[4] From 2001 to 2014, the life expectancy of the richest 1% of Americans averaged 15 years longer than that of the poorest 1%.[5] Furthermore, poorer social classes have worse health outcomes even when they receive the same access to medical care.

Possible sources of SDOH influence

Neighborhoods

Air and water quality

Hazards (lead paint, vermin, mold, dust, infectious disease)

Service availability (schools, transportation, medical care, employment)

Education 

Knowledge of healthy behaviors

Employment opportunities (conditions, compensation)

Economic

Personal income and wealth

Workplace safety (injuries, chemical exposure, repetitive strain)

Work pressures (stress, sleep, social support, financial anxiety)

Social relations

Social harmony (crime, violence, anxiety, social trust)

Racial disadvantages (discrimination, prejudice, animosities)

Community ties (social status, social networks)

Cultural pressures (substance use, illegal activity, diet, exercise)

Feedback cycle between ill-health and poverty

In addition, low-income areas are often healthcare deserts, where there are no providers, or pharmacies, and poor transportation.





Is Everything Health Care? The Overblown Social Determinants of Health | Manhattan Institute

Friday, July 5, 2024

Alzheimer's: AI tool may help predict risk with almost 80% accuracy




Continuing our series of diagnosing and treatment of Alzheimer's disease, the Health Train Express research team discovered this new knowledge base for A.D.

Alzheimer's disease (AD) is the most common cause of dementia and has a long prodromal phase, during which subtle cognitive changes occur. Mild cognitive impairment (MCI) is a stage between normal cognition and AD. Individuals with MCI are at higher risk of developing AD with a 3% to 15% conversion rate of MCI to AD every year.12 Therefore, accurately predicting the progression of MCI to AD can assist physicians in making decisions regarding patient treatment, participation in cognitive rehabilitation programs, and selection for clinical trials involving new drugs.3

Dementia directly affects more than 55 million peopleTrusted Source worldwide, and up to 70% of those people have Alzheimer’s disease, which is characterized by a loss of brain cells associated with the toxic buildup of two proteins, amyloidTrusted Source and tauTrusted Source.

The most common symptoms of Alzheimer’s disease are memory loss, cognitive deficits, problems with speaking, recognition, spatial awareness, reading, or writing, and significant changes in personality and behavior. Since Alzheimer’s is progressive, these symptoms are usually mild at first and tend to become more severe over time. With no cure for the disease, patients and caregivers must approach treatment with medication, lifestyle changes, and support groups. 
AI model may predict Alzheimer’s by analyzing speech patterns


  • Researchers at Boston University say they have designed an artificial intelligence tool that can predict with nearly 80% accuracy whether someone is at risk for developing Alzheimer’s disease based on their speech patterns.
  • The ability to identify potential cognitive decline early has significant potential for mitigating the progression of Alzheimer’s, experts say.
  • However, the sample size used was small, and experts caution that such a tool is not meant to be leaned on as an exclusive method.

  This is from the Alzheimer's Disease Association in the Journal of Alzheimer's

INTRODUCTION

Identification of individuals with mild cognitive impairment (MCI) who are at risk of developing Alzheimer's disease (AD) is crucial for early intervention and selection of clinical trials.

METHODS

We applied natural language processing techniques along with machine learning methods to develop a method for automated prediction of progression to AD within 6 years using speech. The study design was evaluated on the neuropsychological test interviews of n = 166 participants from the Framingham Heart Study, comprising 90 progressive MCI and 76 stable MCI cases.

RESULTS

Our best models, which used features generated from speech data, age, sex, and education level, achieved an accuracy of 78.5% and a sensitivity of 81.1% to predict MCI-to-AD progression within 6 years.

DISCUSSION

The proposed method offers a fully automated procedure, providing an opportunity to develop an inexpensive, broadly accessible, and easy-to-administer screening tool for MCI-to-AD progression prediction, facilitating the development of remote assessment.

Highlights

  • Voice recordings from neuropsychological exams coupled with basic demographics can lead to strong predictive models of progression to dementia from mild cognitive impairment.
  • The study leveraged AI methods for speech recognition and processed the resulting text using language models.
  • The developed AI-powered pipeline can lead to a fully automated assessment that could enable remote and cost-effective screening and prognosis for Alzheimer's disease.

The prevalence of AD increases annually due to the long-term survival of patients, and it produces an increasing expense for long-term care.

Detecting Alzheimer's Disease at an early stage may improve possible treatments.

Detecting early AD could Improve the quality of life for patients and caregivers.

Clinical trials for AD are ongoing by the NIH and have yielded mixed results.

Treatment with either gantenerumab or solanezumab, two monoclonal antibodies, did not slow down cognitive decline in people who have a type of early-onset dementia called dominantly inherited Alzheimer’s disease (DIAD), according to a recent study. However, gantenerumab did reduce some biomarkers of the disease. The study, which was funded in part by NIA, was published in Nature Medicine on June 21. DIAD is a rare form of Alzheimer’s disease. It is an inherited condition caused by mutations in certain genes. People who have DIAD often start having symptoms of dementia, such as confusion and problems with memory, reasoning, and judgment, between the ages of 30 and 50. Currently, there is no treatment to prevent or slow down the disease. In the study, researchers led by a team at Washington University School of Medicine in St. Louis tested whether gantenerumab or solanezumab can effectively treat this condition. This study was part of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). 

Biomarkers for AD

Cerebrospinal fluid (CSF) biomarkers, developed first by Fujirebio more than 25 years ago, have evolved over time from research to specialized diagnostic testing, and from use by early adopters to widespread routine testing today.

Assessing a patient’s CSF allows the detection of four proteins associated with Alzheimer’s disease: two forms of beta-amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and hyperphosphorylated-Tau) proteins. In Alzheimer’s disease amyloid proteins (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) decline to abnormally low levels. The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio may decline long before disease symptoms are manifested. Although still considered a research tool in the US, high total Tau and phospho-Tau levels may also be observed in Alzheimer’s Disease.


There is an urgent clinical need for low-invasive, affordable techniques to assess the risk of Alzheimer's pathology in patients, that could help refer individuals to specialists for confirmatory testing. Plasma-based biomarkers for the two amyloid (Aβ1-42 and Aβ1-40) proteins and for the phospho-Tau protein are already available from Fujirebio for fully automated testing (for research use only). Research continues at the Fujirebio Neurology Center of Excellence, which has led, for example, to the release of new assays from CSF for two promising biomarkers, NPTX2 and sTREM2, and amyloid, both of which are available for research use.  Amyloid is an abnormal protein composed of peptides or peptide fragments.

Amyloid Protein Structure

Histopathology of Amyloid Protein in Brain

MMP-9 is associated with Alzheimer's. MMP can be found in CSF (and/or plasma, Ca clear, colorless fluid that surrounds and protects the brain and spinal cord of vertebratesI. t'Several lines of evidence indicate that there may be an inflammatory component to the pathology of AD. Matrix metalloproteinases (MMPs) remodel the pericellular environment by regulating the cleavage of extracellular matrix proteins, cell surface components, neurotransmitter receptors, and growth factors. The confused abilities of several MMPs to degrade amyloid precursor protein (APP) lead to aggregation of Aβ, as well as the increased expression of MMPs in postmortem brain tissue of AD patients, indicating that MMPs play an important role in the pathogenesis of AD. Their activities are determined through the induction of transcription by inflammatory mediators, through posttranslational modification by free radicals or cytokines and through inhibitory proteins such as tissue inhibitors of metalloproteinases (TIMPs) [].
 roduced by ependymal cells in the brain's ventricles and flows through the subarachnoid spaces of the cranium and spine. CSF has several important functions, including:

Ongoing. Clinical Trials and Research can be found on Pubmed and ClinicalTrials.gov 

The use of PET scans and history combined can afford more specific possibilities.  A positron emission tomography (PET) scan is a nuclear medicine procedure that uses a scanner to create detailed images of the body. The scan measures metabolic activity in body tissues by injecting a small amount of radioactive glucose (sugar) into a vein. The patient then lies on a table that slides through the PET machine while wearing a headrest and white strap to help keep them still. The scanner creates pictures of areas inside the body where the glucose is taken up, with brighter spots indicating higher activity. 

Research is ongoing by many pharma companies. Biogen, Eli Lilly, and Eisai: Three Companies That May Ride the Advancement in Alzheimer's.




Thursday, July 4, 2024

Preventing Alzheimer's Disease

In medical school, we aren’t taught that there are ways to prevent Alzheimer’s disease, when, in fact, we have a lot of power over the direction our brain function will take. However, we’re now learning that the disease starts in the brain 20 to 30 years before the first signs of memory loss! ⁠

This is why we should all be thinking about prevention. ⁠

Here’s the bad news/good news.

Eating sugar and refined carbs can cause pre-dementia and dementia. But cutting out the sugar and refined carbs and adding lots of fat can prevent, and even reverse, pre-dementia and early dementia. Sugar causes pre-diabetes and diabetes, which often leads to significant memory loss.

Chronic stress takes a toll on your body and brain. Stress shrinks the hippocampus, the memory center of the brain. So, find your pause button daily and make time for stress relief. Relaxation isn’t a luxury if you want to prevent or reverse dementia. Whether that involves deep breathing, meditation, or yoga, find something that helps you calm down.

Lack of sleep can cause impaired brain function, leading to CRAFT syndrome, which stands for “can’t remember a _____ thing.” Studies show poor sleep becomes a risk factor for cognitive decline and Alzheimer’s disease. Aim for at least 8 hours of quality sleep every night.

We now know that physical activity can prevent and even slow down the progression of cognitive decline and brain diseases like dementia. Even a 30-minute walk can help. You might want to incorporate high-intensity interval training or weight lifting if you're already more active.

Monday, July 1, 2024

In a Very Important Ruling a Judge strikes down parts of HIPPA

With the advent of Digital Health Information and Electronic Health Records, Congress passed the Health Information Portability and Privacy Act (HIPPA) all members of the health information niche must realize the importance of patient privacy. Each entity signs an agreement that includes the restrictions on health data.  This applies to insurance companies, pharmacies, and any entity which has access to the electronic health care record. Interoperability allows all institutions which need patient health data. This may be provided in a proprietary exchange, such as EPIC, or a disparate data set from other multiple vendors. In order to be certified for interoperability each vendor must be audited by an interoperability certification company

In a nutshell, the ruling decided that hospitals can leak patient data to Meta, TikTok, and other third parties via adtech-installed patient portals, and HHS does not have the authority to enforce HIPAA via the bulletin banning surveillance trackers in December 2022.

This decision has far-reaching implications, especially for patients who rely on robust safeguards for their health information, or who have concerns about patient safety/privacy. The case originated from a wave of federal and state class action lawsuits for leaking data from hospital patient portals. As we navigate this new landscape, it’s crucial to understand what this means for patient privacy and what actions we can take to ensure our voices are heard.

Introduction

  • The Standards for Privacy of Individually Identifiable Health Information ("Privacy Rule") establishes, for the first time, a set of national standards for the protection of certain health information. The U.S. Department of Health and Human Services ("HHS") issued the Privacy Rule to implement the requirement of the Health Insurance Portability and Accountability Act of 1996 ("HIPAA").1 The Privacy Rule standards address the use and disclosure of individuals' health information—called "protected health information" by organizations subject to the Privacy Rule — called "covered entities," as well as standards for individuals' privacy rights to understand and control how their health information is used. Within HHS, the Office for Civil Rights ("OCR") has responsibility for implementing and enforcing the Privacy Rule with respect to voluntary compliance activities and civil money penalties.

    A major goal of the Privacy Rule is to assure that individuals' health information is properly protected while allowing the flow of health information needed to provide and promote high quality health care and to protect the public's health and well being. The Rule strikes a balance that permits important uses of information, while protecting the privacy of people who seek care and healing. Given that the health care marketplace is diverse, the Rule is designed to be flexible and comprehensive to cover the variety of uses and disclosures that need to be addressed.

Who is Covered by the Privacy Rule

The Privacy Rule, as well as all the Administrative Simplification rules, apply to health plans, health care clearinghouses, and to any health care provider who transmits health information in electronic form in connection with transactions for which the Secretary of HHS has adopted standards under HIPAA (the "covered entities"). For help in determining whether you are covered, use CMS's decision tool.

Health Plans. Individual and group plans that provide or pay the cost of medical care are covered entities.4 Health plans include health, dental, vision, and prescription drug insurers, health maintenance organizations ("HMOs"), Medicare, Medicaid, Medicare+Choice and Medicare supplement insurers, and long-term care insurers (excluding nursing home fixed-indemnity policies). Health plans also include employer-sponsored group health plans, government and church-sponsored health plans, and multi-employer health plans. There are exceptions—a group health plan with less than 50 participants that is administered solely by the employer that established and maintains the plan is not a covered entity. Two types of government-funded programs are not health plans: (1) those whose principal purpose is not providing or paying the cost of health care, such as the food stamps program; and (2) those programs whose principal activity is directly providing health care, such as a community health center,5 or the making of grants to fund the direct provision of health care. Certain types of insurance entities are also not health plans, including entities providing only workers' compensation, automobile insurance, and property and casualty insurance. If an insurance entity has separable lines of business, one of which is a health plan, the HIPAA regulations apply to the entity with respect to the health plan line of business.

Health Care Providers. Every health care provider, regardless of size, who electronically transmits health information in connection with certain transactions, is a covered entity. These transactions include claims, benefit eligibility inquiries, referral authorization requests, or other transactions for which HHS has established standards under the HIPAA Transactions Rule.6 Using electronic technology, such as email, does not mean a health care provider is a covered entity; the transmission must be in connection with a standard transaction. The Privacy Rule covers a health care provider whether it electronically transmits these transactions directly or uses a billing service or other third party to do so on its behalf. Health care providers include all "providers of services" (e.g., institutional providers such as hospitals) and "providers of medical or health services" (e.g., non-institutional providers such as physicians, dentists and other practitioners) as defined by Medicare, and any other person or organization that furnishes, bills, or is paid for health care.

Health Care Clearinghouses. Health care clearinghouses are entities that process nonstandard information they receive from another entity into a standard (i.e., standard format or data content), or vice versa.7 In most instances, health care clearinghouses will receive individually identifiable health information only when they are providing these processing services to a health plan or health care provider as a business associate. In such instances, only certain provisions of the Privacy Rule are applicable to the health care clearinghouse's uses and disclosures of protected health information.8 Health care clearinghouses include billing services, repricing companies, community health management information systems, and value-added networks and switches if these entities perform clearinghouse functions.

Business Associates

Business Associate Defined. In general, a business associate is a person or organization, other than a member of a covered entity's workforce, that performs certain functions or activities on behalf of, or provides certain services to, a covered entity that involve the use or disclosure of individually identifiable health information. Business associate functions or activities on behalf of a covered entity include claims processing, data analysis, utilization review, and billing.9 Business associate services to a covered entity are limited to legal, actuarial, accounting, consulting, data aggregation, management, administrative, accreditation, or financial services. However, persons or organizations are not considered business associates if their functions or services do not involve the use or disclosure of protected health information, and where any access to protected health information by such persons would be incidental, if at all. A covered entity can be the business associate of another covered entity.

Business Associate Contract. When a covered entity uses a contractor or other non-workforce member to perform "business associate" services or activities, the Rule requires that the covered entity include certain protections for the information in a business associate agreement (in certain circumstances governmental entities may use alternative means to achieve the same protections). In the business associate contract, a covered entity must impose specified written safeguards on the individually identifiable health information used or disclosed by its business associates.10 Moreover, a covered entity may not contractually authorize its business associate to make any use or disclosure of protected health information that would violate the Rule. Covered entities that had an existing written contract or agreement with business associates prior to October 15, 2002, which was not renewed or modified prior to April 14, 2003, were permitted to continue to operate under that contract until they renewed the contract or April 14, 2004, whichever was first.11 See additional guidance on Business Associates and sample business associate contract language.




 

Thursday, June 27, 2024

FDA Proposes New Warning for Tylenol, Other Brands | The Epoch Times




U.S. drug regulators have proposed adding a new warning to Tylenol and other brands of acetaminophen, an analgesic that relieves pain.

If the proposal from the U.S. Food and Drug Administration (FDA) is finalized, companies that produce the medicines will be required to add a warning that states using acetaminophen may cause severe skin reactions.

A scientific review found that Tylenol and other acetaminophen brands, all available over-the-counter (OTC), can cause severe skin problems like Stevens-Johnson syndrome, according to the FDA’s proposed order.

Some 91 cases of the syndrome or toxic epidermal necrolysis, another rare but severe skin disorder, were reported to the FDA Adverse Event Reporting System from 1969 to 2012, the agency found. An additional 25 cases were reported between Feb. 25, 2012, and June 30, 2020.

Both Stevens-Johnson syndrome and toxic epidermal necrolysis are so severe that they frequently require hospital care and can, in certain cases, result in death.

Regulators also combed through the literature and found 21 cases of the syndrome, the necrolysis, or Acute Generalized Exanthematous Pustulosis reported across 18 articles, after excluding cases that lacked enough detail or featured additional products in addition to acetaminophen. Researchers determined six of the cases were probably related to acetaminophen, with the remaining 15 cases possibly related.

Less severe skin reactions such as rashes and blistering have also been recorded after the use of acetaminophen.

To continue to be generally recognized as safe and effective, or include relevant information for consumers, FDA experts say the products “must include a warning about serious skin reactions.”

The warning, if finalized, would tell consumers that acetaminophen “may cause severe skin reactions” with symptoms including skin reddening, blisters, and rash.

“If a skin reaction occurs, stop use and seek medical help right away,” the proposed warning states.

The proposal “helps to ensure the safety and effectiveness of OTC drugs in our marketplace,” Dr. Theresa Michele, director of the FDA Center for Drug Evaluation and Research’s Office of Nonprescription Drugs, said in a statement.

The proposal follows a 2013 FDA alert that informed people acetaminophen was “associated with” serious skin reactions. The FDA in 2017 also issued guidance for manufacturers recommending they add warnings about the reaction. The new step would require the labels to be updated.

People desiring to comment on the proposed order can submit comments via an FDA portal through the end of July 29. All comments must include “OTC000035” and “Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use.”
If you are interested in the inside effects of OTC (Over-The Counter Products. Click here

FDA Proposes New Warning for Tylenol, Other Brands | The Epoch Times